Language

CAS No. 90098-04-7 | Rebamipide

Name:Rebamipide CAS No.90098-04-7 MF:C19H15ClN2O4 MW:370.79 Purity:97% Package:10g,25g,50g,100g,250g Worldwide Delivery

Categories：

Biochemicals

Email：sale06@alfachem.cn

Inquiry

Chat Now

Product introduction

Introduction and application of CAS No. 90098-04-7 | Rebamipide

Synonyms:(+-)-1,2-dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo-4-quinolinepropanoica;

(+-)-2-(4-chlorobenzoylamino)-3-(2(1h)-quinolinon-4-yl)propionicacid;

Mucosta;

Proamipide;

2-dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo-(+-)-4-quinolinepropanoicacid;

2-(4-Chlorobenzoylamino)-3-(1,2-dihydro-2-oxo-4-quinolyl)propionicacid;

2-(4-CHLOROBENZAMIDO)-3-(2-OXO-1,2-DIHYDROQUINOLIN-4-YL)PROPANOICACID;

OPC-12759,Mucosta,α-[(4-Chlorobenzoyl)-amino]-1,2-dihydro-2-oxo-4-quinolinepropanoicAcid

Specification:

ITEMS	SPECIFICATION
CAS	90098-04-7
MF	C19H15ClN2O4
MW	370.79
Melting point	288-290°C
Boiling point	695.0±55.0 °C
Density	1.394±0.06 g/cm3
Acidity coefficient	3.38±0.10
Color	White
Solubility	Dimethyl sulfoxide: >5mg/mL
Form	Powder
Storage condition	Sealed in dry,Room Temperature

New anti-ulcer drugs:

Rebamipide, also known as rebamipide, is a new type of anti-ulcer drug. It was first launched in Japan in 1990 as a drug for gastric ulcer and acute and chronic gastritis. Rebamipide is a gastric mucosal protective agent that can increase Gastric mucosal blood flow, prostaglandin E2 synthesis and gastric mucus secretion promote the expression of epidermal growth factor and its receptors, which can prevent ulcer occurrence and promote ulcer healing. Studies have shown that it is effective in various experimental gastric ulcers. It can promote the production of prostaglandins in the gastric mucosa and protect the gastric mucosa from various ulcer-causing factors. It is suitable for the treatment of gastric ulcers, acute gastritis, acute exacerbation of chronic gastritis, gastric Mucosal lesions have high clinical application value. Background: With the widespread use of proton pump inhibitors (PPIs) and the eradication of Helicobacter pylori infection as the main means of treating gastric ulcers, the clinical healing rate of peptic ulcers is as high as 80% to 90%, but ulcers are prone to recurrence. Still needs to be resolved. In recent years, the relationship between ulcer healing quality and ulcer recurrence has received increasing attention.

Rebamipide tablets are a mucosal protective drug. The main ingredient of Rebamipide tablets is rebamipide. It is mainly used for gastric ulcer, acute gastritis, acute exacerbation of chronic gastritis, gastric mucosal lesions, such as gastric mucosal erosion, Improvement of bleeding, congestion, and edema.

Package and transportation :

Package: 10g,25g,50g,100g,250g